Jen Morton
Every year around 340,000 people die of pancreatic cancer worldwide. The aim of my lab is to use GEM models to better understand the disease and identify novel therapeutic strategies. To do this, we model different genetic subsets of the disease and use these mice in preclinical trials. Tumours in these models mimic human tumours in terms of the genes altered, but also in terms of the dense desmoplastic stroma of fibroblasts, immune cells, and extracellular matrix proteins, that renders them resistant to most chemotherapy. By studying these mice, we can determine the importance of specific genetic and transcriptomic changes identified in human tumours, identify novel targets for therapy, both in tumour cells and the TME, and test new therapies preclinically.
Abstracts this author is presenting:
